While rapidly acting ketamine does not dock to TDO, we propose that its unique mode of action in MDD therapy is a novel one: that of targeting KMO to undermine neuronal dysfunction, thereby restoring serotonin homeostasis. Here, KMO is linked to major depressive disorder.